Building on Our Impossible Firsts, We Can Change the Course of Human Health

Ionis is unlocking the rapidly expanding potential of RNA- and DNA-targeted medicines to enable better futures for people living with serious diseases.

Man in Glasses & Baseball Cap

Rick

Living with FCS

Our Science and Technology

Rooted in a Deep Understanding of Genetics

The genetic basis of human disease continues to inspire our science and technology as we expand to new therapeutic approaches, while our industry-leading chemistry helps us target the right medicine to the right disease – providing a rich source for future breakthroughs and transformative impact.

WHO WE ARE

Ionis unites groundbreaking science and technology with relentless passion to discover and deliver medicines that enable better futures for people living with serious diseases.

Our commitment to changing lives is a calling that pushes us to deliver the next solution for patients and those who care for them.

Pipeline Icon
OUR PIPELINE

We have set our sights on providing new solutions across the spectrum of diseases, from common intractable neurologic conditions to cardiometabolic disorders to rare diseases and beyond.

Patients & Advocacy Icon
WORKING TO MAKE EVERY LIFE AS FULL AS POSSIBLE

We push beyond the impossible to unleash the potential of patients – and those who care for them – enabling them to make their own impact on the world.

Corporate Responsibility Icon
CORPORATE RESPONSIBILITY

We believe operating responsibly and sustainably creates long-term value and a positive impact for our company, stakeholders, patients, communities and the broader world.

JOIN OUR TEAM

Seizing the Moment to Unlock the Potential of RNA- and DNA-Targeted Medicines

If you’re driven to deliver on the promise of groundbreaking medicines that empower patients and caregivers to make their own impact on the world, come join us.

Man in black and white

LATEST NEWS FEED

 

Sign Up for News Alerts

For the latest on Ionis news and developments

2024-11-06T07:01:00
EST

Positive End of Phase 2 discussion with FDA, including alignment on Phase 3 design Bayley-4 expressive communication selected as Phase 3 study primary endpoint Initiation of ION582 Phase 3 study planned for H1 2025 Ionis to share ION582 program update at the FAST Global Science Summit in November

2024-11-06T07:00:00
EST

WAINUA TM  U.S. launch progressing well; approved in UK ; positive CHMP opinion Olezarsen FCS PDUFA December 19, 2024   Donidalorsen HAE PDUFA August 21, 2025 ; EU regulatory submission in process On track to achieve 2024 P&L financial guidance; increased 2024 cash guidance CARLSBAD, Calif. , Nov.

2024-11-04T09:44:00
EST

Donidalorsen will be a first-in-class RNA-targeted medicine for hereditary angioedema, assuming approval Donidalorsen PDUFA date set for August 21, 2025 Donidalorsen has the potential to be Ionis' second independent commercial launch CARLSBAD, Calif. , Nov.